Dana-Farber Cancer Institute
Boston, MA
Sarah H. Kiskaddon, JD, MA
Ms. Kiskaddon is the Senior Director of the Office of Human Research Studies for the Dana Farber/Harvard Cancer Center. Her academic and professional interests are in the fields of bioethics, and the legal and regulatory issues related to the conduct of clinical and social behavioral research.
Ms. Kiskaddon obtained her law degree from the University of Pittsburgh and Yale Law School, where she was a general editor of the Yale Law and Policy Review. She was admitted to the Connecticut bar and worked in the health law practice of a large law firm in Connecticut before focusing her work on clinical research ethics.
Ms. Kiskaddon has over 25 years of experience in the field of human subject protections, including oversight of Institutional Review Boards, and Scientific Review panels, at Yale University School of Medicine, Connecticut Children's Medical Center, and the Dana Farber Cancer Institute.
Ms. Kiskaddon also served as a Vice President at the Association for the Accreditation of Human Research Protection Programs(AAHRPP). In her role there she observed and advised ethics programs in Argentina, Brazil, China, Colombia, India, Mexico, and the Republic of Korea, on best practices for ethical and regulatory review of research. Many of those institutions went on to become accredited by AAHRPP.
In her current role at the Dana Farber/Harvard Cancer Center. she has focused on both the efficiency of the review process and improving consistency among the IRB panels across serving the DFHCC consortium. She is currently a guest lecturer at the Harvard T.H. Chan Harvard School of Public Health in regulatory and ethics training for clinical investigators.
Ms. Kiskaddon has also published in peer reviewed journals, including the Journal of Experimental Biology, Journal of the American Academy of Pediatrics on the topics of informed consent analysis and IRB balancing of risks and benefits, and fostering communication between parents and adolescents during the consent process. Her current focus is on developing tools to measure and improve consistency and transparancy of IRB decision making.
Wednesday, December 6, 2023
10:15 AM – 11:15 AM ET